TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8889422

Group type: EXPERIMENTAL
Intervention: Priming dose of 0.01 mg kg‐1 followed by 0.07 mg kg‐1 after 3-4 min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Priming dose of 0.015 mg kg‐1 followed by 0.065 mg kg‐1 after 3-4 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single bolus injection of 0.08 mg kg‐1
Number of subjects: 40
Study: 1911500

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 75 micrograms fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3% 2-chloroprocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3% 2-chloroprocaine with 75 micrograms fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 0
Study: 6308441

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg daily p.o.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 31192738

Group type: EXPERIMENTAL
Intervention: 5 ml of honey with an ORS at every diarrhea episode
Number of subjects: 72

Group type: COMPARATOR
Intervention: 10 ml of honey added to an ORS at every diarrhea episode
Number of subjects: 72
Study: 29047408

Group type: EXPERIMENTAL
Intervention: TJ-43 (rikkunshito)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27207028

Group type: EXPERIMENTAL
Intervention: NuvaRing® Applicator
Number of subjects: 325

Group type: COMPARATOR
Intervention: Fingers-only method
Number of subjects: 325
Study: 24578471

Group type: EXPERIMENTAL
Intervention: 1.4% sodium bicarbonate hydration (250 mL) prior to CE-CT
Number of subjects: 570

Group type: COMPARATOR
Intervention: 0.9% saline hydration (1000 mL) prior to and after CE-CT
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: 1.4% sodium bicarbonate hydration
Number of subjects: 570

Group type: COMPARATOR
Intervention: 0.9% saline hydration
Number of subjects: 570
Study: 21840102

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 14
Study: 20579907

Group type: EXPERIMENTAL
Intervention: Eccentric training group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard Treatment Group
Number of subjects: 21
Study: 17852006

Group type: EXPERIMENTAL
Intervention: Strengths-based case management for a six-month period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual self-directed care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case management participants' use of community services
Number of subjects: 0
Study: 16117878

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at a dose of 25.2 to 30.6 Gy in 1.8 to 2.0 Gy per fraction
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no PCI)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 51
Study: 11801880

Group type: EXPERIMENTAL
Intervention: Vaginal cuff brachytherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole pelvic radiation
Number of subjects: 0
Study: 10387387

Group type: EXPERIMENTAL
Intervention: Intervention program based on a multidisciplinary team process
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 500
Study: 1440822

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg twice daily for 21 days
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg once daily for 21 days
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo for 21 days
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Albendazole (both dosages)
Number of subjects: 112
Study: 3698061

Group type: EXPERIMENTAL
Intervention: Microencapsulated potassium chloride (KCl) 60 mEq/day (20 mEq TID)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Wax/polymer matrix tablet 60 mEq/day (20 mEq TID)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Powder-in-liquid formulation 60 mEq/day (20 mEq TID)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 120
Study: 29383408

Group type: EXPERIMENTAL
Intervention: 400 IU of nasal salmon calcitonin daily for three months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 400 IU of nasal salmon calcitonin
Number of subjects: 21
Study: 26850727

Group type: EXPERIMENTAL
Intervention: Mixed-sex CR
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Women-only CR
Number of subjects: 169

Group type: COMPARATOR
Intervention: Home-based CR
Number of subjects: 169
Study: 26418770

Group type: EXPERIMENTAL
Intervention: EIP transfer with neutral wrist positioning (Group I, 12 cases)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EIP transfer with full extension state (Group II, 12 cases)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of thumb motion, grip strength, pinch power, and Disabilities of the Arm, Shoulder, and Hand questionnaire score between Group I and Group II
Number of subjects: 24
Study: 23586624

Group type: EXPERIMENTAL
Intervention: Transperiodontal probing (before incision/BI)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Transsurgical probing (after incision/AI)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Comparison of BI and AI methods
Number of subjects: 9
Study: 22092542

Group type: EXPERIMENTAL
Intervention: Motivational interview in addition to classical consultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard consultation (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational interview
Number of subjects: 0
Study: 18425398

Group type: EXPERIMENTAL
Intervention: UFT (300 mg/day, three days after TACE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (TACE alone)
Number of subjects: 30
Study: 16607097

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12892766

Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy (IRT) with Sr-90
Number of subjects: 138
Study: 10848883

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: DHEA 200 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg and 200 mg
Number of subjects: 9
Study: 9665269

Group type: EXPERIMENTAL
Intervention: Recombinant amino-terminal fragments of BPI
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: BPI treatment
Number of subjects: 900
Study: 8172749

Group type: EXPERIMENTAL
Intervention: Iopentol (300 mg I/ml), 2 ml/kg b.w. with an upper limit of 100 ml
Number of subjects: 110

Group type: COMPARATOR
Intervention: Iohexol (300 mg I/ml), 2 ml/kg b.w. with an upper limit of 100 ml
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both iopentol and iohexol
Number of subjects: 110
Study: 3278434

Group type: EXPERIMENTAL
Intervention: CsA and prednisone (group 1)
Number of subjects: 84

Group type: COMPARATOR
Intervention: P and azathioprine (group 2)
Number of subjects: 84

Group type: COMPARATOR
Intervention: P and ALG (group 3)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Overall comparison of groups
Number of subjects: 84
Study: 29874236

Group type: EXPERIMENTAL
Intervention: Peer-support lifestyle intervention (12-month community-based program with 15 group sessions led by trained lay peer leaders)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: Peer-support lifestyle intervention
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Control group (education booklet with lifestyle change advice)
Number of subjects: 1007
Study: 28401340

Group type: EXPERIMENTAL
Intervention: Right unilateral ultrabrief ECT (RUL UB ECT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Initial seizure threshold (ST)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Percentage change in mid-ictal amplitude
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Percentage change in post-ictal suppression
Number of subjects: 35
Study: 25769330

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 23553534

Group type: EXPERIMENTAL
Intervention: Intravenous zanamivir 600 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous zanamivir 1200 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral moxifloxacin 400 mg (positive control)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous zanamivir placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral moxifloxacin placebo
Number of subjects: 40
Study: 20840754

Group type: EXPERIMENTAL
Intervention: Trospium chloride 15 mg TID
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Oxybutynin hydrochloride 2.5 mg TID
Number of subjects: 1658
Study: 18385265

Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg kg(‐1) for reversal of rocuronium 0.6 mg kg(‐1)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Neostigmine 50 microg kg(‐1) for reversal of cisatracurium 0.15 mg kg(‐1)
Number of subjects: 84
Study: 16679001

Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Haloperidol 3 mg
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 12797397

Group type: EXPERIMENTAL
Intervention: Time-intensified FEC-G (500, 75, 500 every 14 days) with lenograstim (G-CSF 150 microg/m2/day s.c. for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose FEC (500, 75, 500 every 21 days) with lenograstim (G-CSF 150 microg/m2/day s.c. for 10 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time-intensified MMM-G (mitoxantrone 10, methotrexate 35 every 14 days and mitomycin C 10 every 28 days) with lenograstim (G-CSF 150 microg/m2/day s.c. for 10 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time-intensified FEC-G
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose FEC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both intensified regimens (FEC-G and MMM-G)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both anthracycline-containing regimens (FEC-G and standard FEC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both FEC and MMM regimens
Number of subjects: 0
Study: 10895336

Group type: EXPERIMENTAL
Intervention: 3-in-1 mixture of propofol, alfentanil, and mivacurium
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravenous morphine 0.1 mg/kg for intra- and postoperative analgesia
Number of subjects: 50
Study: 8973433

Group type: EXPERIMENTAL
Intervention: Electrical spinal-cord stimulation
Number of subjects: 10
Study: 1577049

Group type: EXPERIMENTAL
Intervention: Intraarticular indomethacin 10 mg
Number of subjects: 10
Study: 3907638

Group type: EXPERIMENTAL
Intervention: Flunarizine (Sibelium)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31379118

Group type: EXPERIMENTAL
Intervention: Magnesium isoglycyrrhizinate (MgIG) low dose (Group A)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Magnesium isoglycyrrhizinate (MgIG) high dose (Group B)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Tiopronin (Group C)
Number of subjects: 174
Study: 29171661

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen at a flow rate of 30-70 l.min-1 via nasal cannulae
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard oxygen therapy at 10 l.min-1 via a bite block
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 60
Study: 27418275

Group type: EXPERIMENTAL
Intervention: mHealth device used over 12 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: mHealth device plus weekly motivational support
Number of subjects: 27

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 27
Study: 24525553

Group type: EXPERIMENTAL
Intervention: Biventricular endocardial pacing (BV-Endo)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Multisite epicardial pacing (MSP-1)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Multisite epicardial pacing (MSP-2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional CRT
Number of subjects: 15
Study: 22196778

Group type: EXPERIMENTAL
Intervention: Triple therapy (aspirin, thienopyridine, and vitamin K antagonist)
Number of subjects: 3320

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy
Number of subjects: 3320
Study: 20691446

Group type: EXPERIMENTAL
Intervention: COX-1 gene polymorphisms (‐842A>G and 50C>T)
Number of subjects: 696

Group type: COMPARATOR
Intervention: Other investigated polymorphisms (GP Ia, GP VI, GP IIIa, PAR‐1, P2Y(12))
Number of subjects: 696
Study: 17377830

Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cashew nut diet
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 64
Study: 16278358

Group type: EXPERIMENTAL
Intervention: Community intervention plus CDSS
Number of subjects: 407460

Group type: COMPARATOR
Intervention: Community intervention alone
Number of subjects: 407460

Group type: EXPERIMENTAL
Intervention: CDSS communities
Number of subjects: 407460
Study: 12095064

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 169

Group type: COMPARATOR
Intervention: Tretinoin 0.1% microsponge gel
Number of subjects: 169
Study: 10194968

Group type: EXPERIMENTAL
Intervention: Response preparation initiated with a precue (colored square)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response preparation during memory scanning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difficulty of concurrent memory search
Number of subjects: 0
Study: 7748046

Group type: EXPERIMENTAL
Intervention: Class I and III antiarrhythmic drugs
Number of subjects: 38072

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 38072

Group type: EXPERIMENTAL
Intervention: Mexiletine hydrochloride and propafenone hydrochloride
Number of subjects: 38072

Group type: EXPERIMENTAL
Intervention: Flecainide acetate
Number of subjects: 38072
Study: 2407200

Group type: EXPERIMENTAL
Intervention: Early repeated cerebrospinal fluid taps
Number of subjects: 157

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 157
Study: 25588

Group type: EXPERIMENTAL
Intervention: Prolyl-leucyl-glycinamide (MIF-I) 75 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Prolyl-leucyl-glycinamide (MIF-I) 750 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31067237

Group type: EXPERIMENTAL
Intervention: Individualized, culturally tailored, computerized decision aid
Number of subjects: 298

Group type: COMPARATOR
Intervention: American College of Rheumatology (ACR) lupus pamphlet
Number of subjects: 298
Study: 26141350

Group type: EXPERIMENTAL
Intervention: Increased information about the perpetrator's background
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Fostering empathy for the victim
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Understanding the violent event
Number of subjects: 834
Study: 26147763

Group type: COMPARATOR
Intervention: Original ICD
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Modified ICD
Number of subjects: 481
Study: 23211634

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV) with hexafluoroethane (C2F6)
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV) with perfluoropropane (C3F8)
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV) with sulfahexafluoride (SF6)
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Internal limiting membrane (ILM) peel
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Repeat surgery for MH
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Repeat surgery for retinal detachment
Number of subjects: 1045
Study: 21698395

Group type: EXPERIMENTAL
Intervention: Thalidomide, dexamethasone, and lovastatin (TDL group)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Thalidomide and dexamethasone (TD group)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Thalidomide and lovastatin (in vitro)
Number of subjects: 91
Study: 18770023

Group type: EXPERIMENTAL
Intervention: Internal and perceived external HIV stigma
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Perceived external stigma
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Internal stigma
Number of subjects: 637
Study: 16310262

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (IS-5-MN)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Standard HF therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Healthy blood donors (control group)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Healthy subjects (second control group)
Number of subjects: 92
Study: 12610404

Group type: EXPERIMENTAL
Intervention: Anesthetic blocks of a compound of bupivacaine with adrenaline associated with clonidine at the frontal branch and sometimes the nasal branch levels of the ophthalmic nerve.
Number of subjects: 20
Study: 11120691

Group type: EXPERIMENTAL
Intervention: Cariporide 120 mg every 8 hours
Number of subjects: 11590

Group type: EXPERIMENTAL
Intervention: Cariporide 20 mg every 8 hours
Number of subjects: 11590

Group type: EXPERIMENTAL
Intervention: Cariporide 80 mg every 8 hours
Number of subjects: 11590

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11590

Group type: EXPERIMENTAL
Intervention: Cariporide 120 mg
Number of subjects: 11590
Study: 9347858

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: H-graft portacaval shunt (HGPCS)
Number of subjects: 80
Study: 8269445

Group type: EXPERIMENTAL
Intervention: 3-mg tablets of reformulated, micronized glyburide (Glynase PresTab tablets)
Number of subjects: 206

Group type: COMPARATOR
Intervention: 5-mg tablets of original glyburide (Micronase tablets)
Number of subjects: 206
Study: 3884218

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (4 mg/kg/day)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (0.35 mg/kg/day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 31694851

Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil (loading dose of 0.4 mg/kg in 3 hours; followed by continuous infusion of 1.6 mg/kg/day)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Inhaled nitric oxide (iNO) (dosed at 20 ppm)
Number of subjects: 330
Study: 30299148

Group type: EXPERIMENTAL
Intervention: Right arm immobilization for 8 hours
Number of subjects: 14

Group type: COMPARATOR
Intervention: No immobilization (control) for 8 hours
Number of subjects: 14
Study: 26940151

Group type: EXPERIMENTAL
Intervention: High fruit and soybean products diet
Number of subjects: 187

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 187

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 187
Study: 25158846

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard moist wound therapy
Number of subjects: 0
Study: 22083885

Group type: EXPERIMENTAL
Intervention: Submandibular gland transfer
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no gland transfer)
Number of subjects: 38
Study: 20028364

Group type: EXPERIMENTAL
Intervention: Bourbon
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Vodka
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (matched control)
Number of subjects: 95
Study: 17293706

Group type: EXPERIMENTAL
Intervention: Metformin (850-2550 mg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 37
Study: 16120456

Group type: EXPERIMENTAL
Intervention: web‐based assessment and personalized feedback (n = 72)
Number of subjects: 218

Group type: COMPARATOR
Intervention: assessment only (n = 74)
Number of subjects: 218

Group type: COMPARATOR
Intervention: minimal contact (n = 72)
Number of subjects: 218
Study: 11973011

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 84

Group type: COMPARATOR
Intervention: Active placebo (benztropine mesylate)
Number of subjects: 84
Study: 10411245

Group type: EXPERIMENTAL
Intervention: Sarns oxygenator with 0.0375 g of albumin/100 ml prime
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sarns oxygenator with 0.125 g of albumin/100 ml prime
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Medtronic oxygenator with 0.0375 g of albumin/100 ml prime
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Medtronic oxygenator with 0.125 g of albumin/100 ml prime
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sarns oxygenator with no albumin in the prime
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medtronic oxygenator with no albumin in the prime
Number of subjects: 80
Study: 7501747

Group type: EXPERIMENTAL
Intervention: Listening to a Mozart sonata for 10 minutes
Number of subjects: 51

Group type: COMPARATOR
Intervention: Meditating in silence for 10 minutes
Number of subjects: 51
Study: 2083406

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid treatment (beclomethasone)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7285309

Group type: EXPERIMENTAL
Intervention: Intense aerobic training (50-minute jogging sessions 5 days a week at 85% of maximal heart rate)
Number of subjects: 36
Study: 31023704

Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy
Number of subjects: 432

Group type: COMPARATOR
Intervention: Control group (no preoperative physiotherapy)
Number of subjects: 432
Study: 28832441

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention (CBI)
Number of subjects: 701
Study: 25442992

Group type: EXPERIMENTAL
Intervention: Postoperative atrial fibrillation (POAF) patients
Number of subjects: 2096
Study: 23714653

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5993

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5993
Study: 21334852

Group type: EXPERIMENTAL
Intervention: Taurine supplementation (500 mg three times a day for 2 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29